Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era.

Ingiliz P, Wehmeyer MH, Boesecke C, Schulze Zur Wiesch J, Schewe K, Lutz T, Baumgarten A, Simon KG, Hueppe D, Rockstroh JK, Mauss S, Christensen S; NEAT study group; GECCO study group.

Clin Infect Dis. 2019 Sep 28. pii: ciz949. doi: 10.1093/cid/ciz949. [Epub ahead of print]

PMID:
31562816
2.

Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

Graf C, Mücke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, Zeuzem S, Herrmann E, Vermehren J.

Clin Infect Dis. 2019 Sep 12. pii: ciz696. doi: 10.1093/cid/ciz696. [Epub ahead of print]

PMID:
31513710
3.

Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis.

Martin NK, Jansen K, An der Heiden M, Boesecke C, Boyd A, Schewe K, Baumgarten A, Lutz T, Christensen S, Thielen A, Mauss S, Rockstroh JK, Skaathun B, Ingiliz P.

J Infect Dis. 2019 Oct 8;220(10):1635-1644. doi: 10.1093/infdis/jiz367.

PMID:
31301142
4.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group.

Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2.

5.

Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe.

Yoshida K, Post G, Shimakawa Y, Thursz M, Brown A, Ingiliz P, Lemoine M.

J Hepatol. 2019 Jun;70(6):1295-1297. doi: 10.1016/j.jhep.2019.03.008. Epub 2019 Apr 11. No abstract available.

PMID:
30982592
6.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.

PMID:
30982526
7.

Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection.

Post G, Shalev N, Baumgarten A, Shimakawa Y, Lemoine M, Krznaric I, Dupke S, Carganico A, Arastéh K, Ingiliz P.

Eur J Gastroenterol Hepatol. 2019 Jun;31(6):723-728. doi: 10.1097/MEG.0000000000001409.

PMID:
30964812
8.

Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?

Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group.

J Clin Gastroenterol. 2019 Feb 15. doi: 10.1097/MCG.0000000000001189. [Epub ahead of print]

PMID:
30789853
9.

Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.

Mauss S, Buendgens L, Christensen S, Ingiliz P, Berger F, Hüppe D, Simon KG, Lutz T, Schewe K, Boesecke C, Tacke F.

Z Gastroenterol. 2019 Feb;57(2):139-147. doi: 10.1055/a-0752-0514. Epub 2019 Feb 12.

PMID:
30754058
10.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

PMID:
30570529
11.

Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.

Shimakawa Y, Njie R, Ndow G, Vray M, Mbaye PS, Bonnard P, Sombié R, Nana J, Leroy V, Bottero J, Ingiliz P, Post G, Sanneh B, Baldeh I, Suso P, Ceesay A, Jeng A, Njai HF, Nayagam S, D'Alessandro U, Chemin I, Mendy M, Thursz M, Lemoine M.

J Hepatol. 2018 Oct;69(4):776-784. doi: 10.1016/j.jhep.2018.05.024. Epub 2018 Jul 1.

12.

Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients.

Ingiliz P, Canbay A.

Aliment Pharmacol Ther. 2018 Jun;47(11):1551-1552. doi: 10.1111/apt.14649. No abstract available.

PMID:
29878428
13.

Interferon-free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health.

Kleefeld F, Heller S, Ingiliz P, Jessen H, Petersen A, Kopp U, Kraft A, Hahn K.

J Neurovirol. 2018 Oct;24(5):557-569. doi: 10.1007/s13365-018-0647-z. Epub 2018 May 21.

PMID:
29785584
14.

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.

von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 May;47(9):1288-1295. doi: 10.1111/apt.14592. Epub 2018 Mar 14.

PMID:
29536554
15.

Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).

Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network.

Liver Int. 2018 May;38(5):842-850. doi: 10.1111/liv.13604. Epub 2017 Oct 26.

PMID:
28963781
16.

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection.

Boesecke C, Ingiliz P, Berger F, Lutz T, Schewe K, Schulze Zur Wiesch J, Baumgarten A, Christensen S, Rockstroh JK, Mauss S; GECCO Study Group.

Open Forum Infect Dis. 2017 Jul 27;4(3):ofx158. doi: 10.1093/ofid/ofx158. eCollection 2017 Summer.

17.

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).

Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J.

J Med Virol. 2018 Feb;90(2):304-312. doi: 10.1002/jmv.24903. Epub 2017 Nov 9.

PMID:
28710853
18.

Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group.

HIV Med. 2018 Jan;19(1):65-71. doi: 10.1111/hiv.12532. Epub 2017 Jul 13.

PMID:
28703491
19.

HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

Steininger K, Boyd A, Dupke S, Krznaric I, Carganico A, Munteanu M, Neifer S, Schuetze M, Obermeier M, Arasteh K, Baumgarten A, Ingiliz P.

J Viral Hepat. 2017 Oct;24(10):832-839. doi: 10.1111/jvh.12707. Epub 2017 Apr 25.

PMID:
28439936
20.

Reply to: "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".

Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V.

J Hepatol. 2017 Aug;67(2):420-422. doi: 10.1016/j.jhep.2017.03.033. Epub 2017 Apr 12. No abstract available.

PMID:
28412291

Supplemental Content

Loading ...
Support Center